Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Elevated interstitial fluid pressure, a hallmark of solid tumors, can compromise the delivery of therapeutics to tumors. Here we show that blocking vascular endothelial growth factor (VEGF) signaling by DC101 (a VEGF-receptor-2 antibody) decreases interstitial fluid pressure, not by restoring lymphatic function, but by producing a morphologically and functionally “normalized” vascular network. We demonstrate that the normalization process prunes immature vessels and improves the integrity and function of the remaining vasculature by enhancing the perivascular cell and basement membrane coverage. We also show that DC101 induces a hydrostatic pressure gradient across the vascular wall, which leads to a deeper penetration of molecules into tumors. Thus, vascular normalization may contribute to the improved survival rates in tumor-bearing animals and in colorectal carcinoma patients treated with an anti-VEGF antibody in combination with cytotoxic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical data indicate that anti-VEGF therapy results in vascular normalization via pruning of immature blood vessels, which have poor pericyte coverage, and via active pericyte recruitment62,69”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An intermediate dose of anti-VEGF receptor two antibodies (DC101) was used to successfully normalize the blood vasculature in and around the tumor site, thereby reducing the necrotic and hypoxic regions [25].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This concludes the DC101 improved tumor vascular normalization leading to a smaller and homogenous pore on the tumor vessel wall [25].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529 · cited 3×
“Ang2 has been shown to destabilize blood vessel (7), thus the reduction in Ang2 expression may contribute to a more stable vasculature as described above.”
BackgroundSelf-citationRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438 · cited 2×
“5 nm)/vessel pore size (500 nm)](2)](2)) (26).”
BackgroundSelf-citationNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 2×
“The data presented here provide compelling evidence in support of the normalization hypothesis: that judicious application of antiangiogenic treatment can normalize the tumor vasculature by pruning the immature vessels and fortifying the remaining ones (2).”
BackgroundSelf-citationWillett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966 · cited 1×
“We have recently shown that an anti-VEGF antibody can lower interstitial fluid pressure (IFP) in transplanted tumors in mice (3) and in rectal carcinomas in patients (4).”
BackgroundSelf-citationBrowder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241 · cited 1×
“This result implies that vessels with less mural cell coverage are more vulnerable to DC101-induced regression, which is consistent with previous findings that tumor vessels without mural cells tend to regress after VEGF withdrawal (21).”
ResultKlement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Self-citationAbnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors
Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., & McDonald, D. M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64920-6 · Cited by 983 · cited 2×
“The mice were perfused and fixed with 4% paraformaldehyde, and 100- m-thick sections were prepared (13).”
BackgroundMethodSelf-citationLymphatic Metastasis in the Absence of Functional Intratumor Lymphatics
Padera, T. P., Kadambi, A., di Tomaso, E., Carreira, C. M., Brown, E. B., Boucher, Y., Choi, N. C., Mathisen, D., Wain, J., Mark, E. J., et al. (2002) · Science · doi:10.1126/science.1071420 · Cited by 967 · cited 2×
“In tumors, IFP homeostasis is perturbed because of impaired lymphatic function (5, 6) and abnormalities in vascular structure and function (7).”
BackgroundMethodSelf-citationInterstitial-lymphatic mechanisms in the control of extracellular fluid volume
Aukland, K., & Reed, R. K. (1993) · Physiological Reviews · doi:10.1152/physrev.1993.73.1.1 · Cited by 934
Research works printed but not linked: 1
- Parker JC, Perry MA, Taylor AE. Permeability of the microvascular barrier Staub NC Taylor AE eds. . Edema, p. 143-87, Raven Press New York 1984.
Cited by
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationDelivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
“Blockade of VEGF causes pruning of immature vessels, decrease in vessel density and diameter, and remodeling of the vasculature to more closely resemble the structure of normal vessels”
BackgroundSelf-citationRole of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Self-citationDrug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
“, and changes in the above parameters have been quantified in response to various treatment”
BackgroundVEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Metadata
- Authors
- Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K.
- Affiliations
- Harvard University (US)
- 3ImClone Systems, Incorporated, New York, New York
- Venue
- Cancer Research
- Published
- 2004-06-01
- Volume
- 64
- Issue
- 11
- Pages
- 3731-3736
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1977887541
- Cited by
- 1,189
- References
- 30
- Citations by year
- 2026: 20 · 2025: 30 · 2024: 28 · 2023: 56 · 2022: 38 · 2021: 51 · 2020: 48 · 2019: 55 · 2018: 45 · 2017: 59 · 2016: 58 · 2015: 49 · 2014: 47 · 2013: 60 · 2012: 84
- FWCI
- 21.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- National Cancer Institute (P01CA080124, P01-CA-80124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- vascular normalization, VEGF receptor 2, DC101, anti-VEGF antibody, interstitial fluid pressure, tumor vasculature, hydrostatic pressure gradient, drug penetration, tumor microenvironment, basement membrane, perivascular cells, colorectal cancer, combination therapy
- MeSH terms
- Animals, Antibodies, Capillary Permeability, Humans, Hydrostatic Pressure, Neoplasms, Neovascularization, Pathologic, Serum Albumin, Bovine, Mice, SCID, Vascular Endothelial Growth Factor Receptor-2, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-0074
- The paper
- Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004). Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-0074
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.